UK Biochips Market (2025-2030)
The UK Biochips Market was valued at $661.4 Million in 2025 and projected to reach to $1055.9 Million by 2030, representing a compound annual growth rate of 9.8%. The UK biochips market is poised for sustained expansion through 2030, driven by increasing adoption in clinical diagnostics, drug discovery acceleration, and personalized medicine applications.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Biochips Market Trends and Insights
- The UK's advanced healthcare infrastructure and strong investment in precision medicine are driving adoption of biochip technologies across diagnostics, drug discovery, and personalized treatment applications.
- The UK's position as a life sciences hub, combined with regulatory support and academic research excellence, positions the market for accelerated expansion through 2030. The UK biochips sector benefits from increasing demand for point-of-care diagnostics and miniaturized laboratory solutions.
- UK healthcare providers and pharmaceutical companies are integrating biochip platforms to enhance clinical efficiency and reduce time-to-diagnosis.
- The UK's commitment to digital health and genomic medicine initiatives further supports market penetration, with growing adoption among NHS trusts and private healthcare facilities. Key drivers for the UK market include rising chronic disease prevalence, aging demographics, and substantial R&D spending by UK-based biotech firms.
- The UK's regulatory environment and collaboration between academic institutions and industry accelerate innovation cycles.
- By 2030, the UK biochips market is expected to capture significant value as healthcare systems increasingly prioritize rapid, cost-effective diagnostic solutions..
Key Market Statistics
- CAGR (2025-2030) 9.8% CAGR
- Market Size, 2025 ~USD 661.4 Million
- Forecast, 2030 ~USD 1055.9 Million
- Country UK
UK Biochips Market Overview
Market Valuation Growth :
The UK biochips market is valued at £661.4 million in 2025, with a projected expansion to £1,055.9 million by 2030, representing a robust 9.8% CAGR over the forecast period.
Advanced Healthcare Infrastructure :
The UK's world-class NHS and private healthcare systems provide an ideal environment for biochip adoption, with strong institutional support for innovative diagnostic and therapeutic technologies.
Precision Medicine Leadership :
Significant UK investment in precision medicine initiatives and genomic research is accelerating biochip integration across personalized treatment pathways and patient stratification applications.
Life Sciences Hub Status :
The UK's established position as a global life sciences hub, with leading research institutions and biotech clusters, drives continuous innovation and commercialization of biochip technologies.
UK Biochips Market Dynamics
- Government backing for life sciences research and the NHS's digital transformation initiatives create favorable conditions for biochip technology deployment across healthcare settings.
- The market's 9.8% CAGR reflects growing demand from pharmaceutical companies, diagnostic laboratories, and academic research institutions seeking advanced analytical capabilities. Key growth catalysts include rising prevalence of chronic diseases requiring early detection, expanding point-of-care testing requirements, and integration of biochips into companion diagnostic frameworks.
- UK regulatory frameworks supporting medical device innovation, combined with substantial R&D investments from both public and private sectors, position the country as a leading adopter of next-generation biochip solutions within Europe..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The UK biochips market is projected to grow from £661.4M (2025) to £1,055.9M (2030) at a 9.8% CAGR, outpacing global growth.
- The UK's advanced life sciences ecosystem and NHS integration drive strong adoption of biochip diagnostics and personalized medicine platforms.
- Regulatory support and academic-industry collaboration in the UK accelerate innovation and commercialization of biochip technologies.
- Rising demand for point-of-care diagnostics and genomic medicine initiatives position the UK as a key European biochips market through 2030.
Biochips Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MICROFLUIDICS (Fabrication Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.8% from 2025 to 2030 |
| Largest Segment | MICROARRAYS (Fabrication Technology) |
| Market Size Base Year (Billions) | ~USD 14.01 (2025) |
| Revenue Forecast (Billions) | ~USD 21.36 (2030) |
| Segments Covered | Products & Services, Type, Application, Fabrication Technology, End User, Product & Service |
UK Biochips Market Report Segmentation
6 segment dimensions are covered across the global market.
By Products & Services
- Consumables
- Instruments
- Software & Services
By Type
- Cell Arrays
- Dna Chips
- Lab-On-A-Chip
- Protein Chips
- Tissue Arrays
By Application
- Agricultural Biotechnology
- Cancer Diagnosis & Treatment
- Clinical Diagnostic
- Diagnostics
- Drug Discovery
- Expression Profiling
- Gene Expression
- Genomics
- High-Throughput Screening
- Ivd & Poc
- Other Dna Chip Applications
- Other Loac Applications
- Other Protein Chip Applications
- Proteomics
- Snp Genotyping
By Fabrication Technology
- Microarrays
- Microfluidics
By End User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
- Hospitals & Diagnostic Centers
- Other End Users
By Product & Service
- Consumables
- Instruments
- Software & Services
UK: BIOCHIPS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 59.1 | 64.5 | 70.4 | 77 | 84.1 | 91.9 | 100.6 | 110.2 | 9.4 |
| BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES | 305.4 | 336.3 | 370.4 | 408.3 | 450 | 496.5 | 548.3 | 606 | 10.3 |
| CONTRACT RESEARCH ORGANIZATIONS | 36.3 | 40.3 | 44.8 | 49.8 | 55.4 | 61.7 | 68.7 | 76.6 | 11.3 |
| HOSPITALS & DIAGNOSTIC CENTERS | 125 | 135.1 | 146.1 | 158 | 170.9 | 185 | 200.5 | 217.5 | 8.3 |
| OTHER END USERS | 25 | 27.2 | 29.6 | 32.3 | 35.1 | 38.3 | 41.7 | 45.6 | 9 |
| TOTAL | 551 | 603.5 | 661.4 | 725.4 | 795.5 | 873.4 | 959.9 | 1055.9 | 9.8 |
Target Audience
- Pharmaceutical & Biotech Companies : UK-based and international pharma firms need market intelligence to guide biochip integration into drug discovery pipelines, clinical trial designs, and companion diagnostic development strategies.
- Diagnostic Laboratory Operators : Clinical and pathology laboratories across the UK require data on biochip adoption trends, technology ROI, and implementation best practices to enhance testing capabilities and operational efficiency.
- NHS Trust & Hospital Administrators : Healthcare procurement and innovation teams need UK market insights to evaluate biochip technologies for diagnostic deployment, assess vendor capabilities, and justify capital investments to leadership.
- Medical Device & Biochip Manufacturers : Equipment and biochip developers require detailed UK market analysis to identify growth segments, understand customer needs, benchmark competitive offerings, and optimize product-market fit strategies.
- Investment & Venture Capital Firms : UK-focused investors and venture funds need comprehensive market data to identify promising biochip startups, assess market timing, evaluate exit opportunities, and support portfolio company growth strategies.
Key Companies in the UK Biochips Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects, |
| JABIL | United States | Public Company | Regulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem), |
| AT&S | Canada | Public Company | Turnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration, |
| X-FAB | Belgium | Public Company | Automotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes), |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other, |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents), |
| CEPHEID | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics), |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| REVVITY | United States | Public Company | Diagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
DECODE GENETICS
Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.
JABIL
Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.
AT&S
AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.
X-FAB
X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.
GE HEALTHCARE
GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
ILLUMINA, INC.
Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.
QIAGEN
Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
ABBOTT
Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.
STANDARD BIOTOOLS
Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.
10X GENOMICS
10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.
CEPHEID
Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.
REVVITY
Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.
Reasons to Buy this Report
- UK-Specific Market Sizing : Access precise valuation data for the UK biochips market with country-level forecasts through 2030, enabling accurate budget allocation and market entry strategies tailored to the British healthcare landscape.
- Regulatory & Healthcare Insights : Understand UK-specific regulatory pathways, NHS procurement processes, and healthcare system integration requirements that directly impact biochip commercialization and adoption timelines.
- Competitive Landscape Analysis : Identify key UK-based and international players operating in the biochips space, their market positioning, partnerships with NHS trusts, and strategic initiatives within the British market.
- Investment & Growth Opportunities : Discover high-potential segments within UK diagnostics, drug discovery, and personalized medicine where biochip technologies are gaining traction and attracting venture capital and government funding.
- Strategic Decision Support : Leverage UK market intelligence to inform product development priorities, partnership strategies, and go-to-market approaches aligned with NHS requirements and British life sciences ecosystem dynamics.
Frequently asked questions
What is the current size of the UK biochips market?
The UK biochips market was valued at £661.4 million in 2025 and is expected to reach £1,055.9 million by 2030.
What is the growth rate of the UK biochips market?
The UK biochips market is growing at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2030.
What are the main applications of biochips in the UK?
The UK biochips market serves diagnostics, drug discovery, personalized medicine, and point-of-care testing applications across NHS and private healthcare facilities.
Which factors are driving growth in the UK biochips market?
Key drivers include the UK's advanced healthcare infrastructure, precision medicine investments, aging population, chronic disease prevalence, and strong R&D spending by UK biotech firms.
How does the UK biochips market compare to global trends?
The UK biochips market is growing at 9.8% CAGR, which exceeds the global average of 8.8%, reflecting the UK's strong life sciences ecosystem and healthcare innovation focus.
RESEARCH METHODOLOGY
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Get the Full Biochips Market Report
Full forecast, segment splits, and company analysis for all Biochips Market.
- Canada Biochips Market
- US Biochips Market
- Germany Biochips Market
- France Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- Netherlands Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Thailand Biochips Market
- New Zealand Biochips Market
- Brazil Biochips Market
- Mexico Biochips Market
- Rest Of Europe Biochips Market
- Rest Of Asia Pacific Biochips Market
- Rest Of Latin America Biochips Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
